Randomized, blinded, placebo-controlled clinical trial of n-acetylcysteine in dogs with spinal cord trauma from acute intervertebral disc disease

Spine

Volumn 33, Issue 13, 2008, Pages 1397-1402

  Baltzer, Wendy I ^a   McMichael, Maureen A ^b   Hosgood, Giselle L ^c   Kerwin, Sharon C ^b   Levine, Jonathan M ^b   Steiner, Jorg M ^b   Ruaux, Craig G ^a  

^a OREGON STATE UNIVERSITY   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Disk; Isoprostanes; N acetylcysteine; Spine injury

Indexed keywords

ACETYLCYSTEINE; ISOPROSTANE; SODIUM CHLORIDE; 8 EPI PROSTAGLANDIN F2ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; ANTIOXIDANT; BIOLOGICAL MARKER; DRUG DERIVATIVE; PROSTAGLANDIN F2 ALPHA;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG EXCRETION; FEMALE; INTERVERTEBRAL DISK DISEASE; LAMINECTOMY; MALE; NEUROLOGIC EXAMINATION; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SPINAL CORD INJURY; URINARY EXCRETION; ANIMAL; ANIMAL DISEASE; DISEASE MODEL; DOG DISEASE; INTERVERTEBRAL DISK; INTERVERTEBRAL DISK HERNIA; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; RANDOMIZATION; TIME; URINE;

ACETYLCYSTEINE; ANIMALS; ANTIOXIDANTS; BIOLOGICAL MARKERS; DINOPROST; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; FEMALE; INFUSIONS, INTRAVENOUS; INTERVERTEBRAL DISK; INTERVERTEBRAL DISK DISPLACEMENT; LAMINECTOMY; MALE; OXIDATIVE STRESS; RANDOM ALLOCATION; SPINAL CORD INJURIES; TIME FACTORS;

EID: 46749106748     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3181753c37     Document Type: Article

References (44)

1. Hoerlin BF. Intervertebral Disc Disease In: Oliver JE, Hoerlin BF, Mayhew IG, eds. Veterinary Neurology. Philadelphia: WB Saunders Co; 1987; 321-41.
2. Toombs JP. Intervertebral Disc Disease In: Slatter D, ed. Textbook of Small Animal Surgery. Philadelphia: WB Saunders Co; 2003;1193-209.
3. Olby N. Current concepts in the management of acute spinal cord injury. J Vet Intern Med 1999;13:399-407.
4. Braughler JM, Hall ED. Involvement of lipid peroxidation in CNS injury. J Neurotrauma 1992;9 (suppl 1):S1-S7.
5. Lucas JH, Wheeler DG, Guan Z, et al. Effect of glutathione augmentation on lipid peroxidation after spinal cord injury. J Neurotrauma 2002; 19:763-75.
6. Slatter D, Jerran RM, Dewey CW. Acute thoracolumbar disc extrusion in dogs-Part 1. Compend Contin Educ Prac Vet 1999;21:922.
7. Juurlink BH, Paterson PG. Review of oxidative stress in brain and spinal cord injury: suggestions for pharmacological and nutritional management strategies. J Spinal Cord Med 1998;21:309-34.
8. Cracowski JL, Durand T, Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol Sci 2002;23:360-6.
9. Azbill RD, Mu X, Bruce-Keller AJ, et al. Impaired mitochondrial function, oxidative stress and altered antioxidant enzyme activities following traumatic spinal cord injury. Brain Res 1997;765:283-90.
10. Morrow JD, Roberts LJ. The isoprostanes: their role as an index of oxidant stress status in human pulmonary disease. Am J Respir Crit Care Med 2002; 166:S25-S30.
11. McMichael MA, Ruaux CG, Baltzer WI, et al. Concentrations of 15F2t isoprostane in urine of dogs with intervertebral disk disease. Am J Vet Res 2006;67:1226-31.
12. Romero FJ, Monsalve E, Hermenegildo C, et al. Oxygen toxicity in the nervous tissue: comparison of the antioxidant defense of rat brain and sciatic nerve. Neurocbem Res 1991;16:157-61.
13. Amar AP, Levy ML. Pathogenesis and pharmacological strategies for mitigating secondary damage in acute spinal cord injury. Neurosurgery 1999; 44:1027-39.
14. Blight AR, Zimber MP. Acute spinal cord injury: pharmacotherapy and drug development perspectives. Curr Opin Investig Drugs 2001;2:801-8.
15. Hanson SM, Bostwick DR, Twedt DC, et al. Clinical evaluation of cimetidine, sucralfate, and misoprostol for prevention of gastrointestinal tract bleeding in dogs undergoing spinal surgery. Am J Vet Res 1997;58:1320-3.
16. Hurlbert RJ. The role of steroids in acute spinal cord injury: an evidence-based analysis. Spine 2001;26:S39-S46.
17. Zafarullah M, Li WQ, Sylvester J, et al. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 2003;60:6-20.
18. Hicdonmez T, Kanter M, Tiryaki M, et al. Neuroprotective effects of N-acetylcysteine on experimental closed head trauma in rats. Neurochem Res 2006;31:473-81.
19. Cakir O, Erdem K, Oruc A, et al. Neuroprotective effect of N-acetylcysteine and hypothermia on the spinal cord ischemia-reperfusion injury. Cardiovasc Surg 2003;11:375-9.
20. Henderson JT, Javaheri M, Kopko S, et al. Reduction of lower motor neuron degeneration in wobbler mice by N-acetyl-L-cysteine. J Neurosci 1996;16: 7574-82.
21. Sochman J. N-acetylcysteine in acute cardiology: 10 years later: what do we know and what would we like to know?! J Am Coll Cardiol 2002;39: 1422-8.
22. Bailey B, McGuigan MA. Management of anaphylactoid reactions to intravenous N-acetylcysteine. Ann Emerg Med 1998;31:710-5.
23. Mant TG, Tempowski JH, Volans GN, et al. Adverse reactions to acetylcysteine and effects of overdose. Br Med J (Clin Res Ed) 1984;289:217-9.
24. Evans HE, de Lahunta A. The skeletal and muscular systems. Miller's Guide to the Dissection of the Dog. 4th ed. Philadelphia: WB Saunders; 1996;6-118.
25. Institute of Laboratory Animal Resources NRC. Guide to the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.
26. Frankel HL, Hancock DO, Hyslop G, et al. The value of postural reduction in the initial management of closed injuries of the spine with paraplegia and tetraplegia. I. Paraplegia 1969;7:179-92.
27. Priester WA. Canine intervertebral disk disease occurrence by age, breed, and sex among 8,117 cases. Theriogenology 1976;6:293-303.
28. Meister A. Glutathione, ascorbate and cellular protection. Cancer Res 1994; 54:S1969-S1975.
29. Sevillano S, de Dios I, de la Mano AM, et al. N-acetylcysteine induces beneficial changes in the acinar cell cycle progression in the course of acute pancreatitis. Cell Prolif 2003;36:279-89.
30. Tepel M, van der Giet M, Statz M, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003;107:992-5.
31. Birck R, Krzossok S, Markowetz F, et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003;362:598-603.
32. Arakawa M, Ishimura A, Arai Y, et al. N-Acetylcysteine and ebselen but not nifedipine protected cerebellar granule neurons against 4-hydroxynonenal- induced neuronal death. Neurosci Res 2007;57:220-9.
33. Sury MD, Frese-Schaper M, Muhlemann MK, et al. Evidence that N-acetylcysteine inhibits TNF-alpha-induced cerebrovascular endothelin-1 upregulation via inhibition of mitogen- and stress-activated protein kinase. Free Radic Biol Med 2006;41:1372-S3.
34. Boga M, Discigil B, Ozkisacik EA, et al. The combined effect of iloprost and N-acetylcysteine in preventing spinal cord ischemia in rabbits. Eur J Vasc Endovasc Surg 2006;31:366-72.
35. Thomale UW, Griebenow M, Kroppenstedt SN, et al. The effect of N-acetylcysteine on posttraumatic changes after controlled cortical impact in rats. Intensive Care Med 2006;32:149-55.
36. McLellan LI, Lewis AD, Hall DJ, et al. Uptake and distribution of N-acetylcysteine in mice: tissue-specific effects on glutathione concentrations. Carcinogenesis 1995;16:2099-106.
37. Farr SA, Poon HF, Dogrukol-Ak D, et al. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMPS mice. J Neurochem 2003;84:1173-83.
38. Karageorgos N, Patsoukis N, Chroni E, et al. Effect of N-acetylcysteine, allopurinol and vitamin E on jaundice-induced brain oxidative stress in rats. Brain Res 2006;1111:203-12.
39. Plumb DC. Veterinary Drug Handbook. 5th ed. Ames: Iowa State University Press; 2005.
40. Offen D, Gilgun-Sherki Y, Barhum Y, et al. A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis. J Neurochem 2004;89:1241-51.
41. Gilgun-Sherki Y, Barhum Y, Atlas D, et al. Analysis of gene expression in MOG-induced experimental autoimmune encephalomyelitis after treatment with a novel brain-penetrating antioxidant. J Mol Neurosci 2005;27: 125-35.
42. Yin H, Porter NA. New insights regarding the autoxidation of polyunsaturated fatty acids. Antioxid Redox Signal 2005;7:170-84.
43. Moore K, Roberts LJ, 2nd. Measurement of lipid peroxidation. Free Radic Res 1998;28:659-71.
44. Moore K. Isoprostanes and the liver. Chem Phys Lipids 2004;128:125-33.